Evidence map›Paper›PMID 32909387›Full record

Trial reportJournal of the International AIDS Society2020

Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi.

Brooke E Nichols, O Agatha Offorjebe, Refiloe Cele, Frackson Shaba, Kelvin Balakasi, Mackenzie Chivwara, Risa M Hoffman, Lawrence C Long, Sydney Rosen, Kathryn Dovel

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Brooke E NicholsDepartment of Global Health, School of Public Health, Boston University, Boston, MA, USA.ORCID 0000-0003-4682-4999
O Agatha OfforjebeDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Refiloe CeleHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Frackson ShabaPartners in Hope, Lilongwe, Malawi.
Kelvin BalakasiPartners in Hope, Lilongwe, Malawi.
Mackenzie ChivwaraPartners in Hope, Lilongwe, Malawi.
Risa M HoffmanPartners in Hope, Lilongwe, Malawi.
Lawrence C LongDepartment of Global Health, School of Public Health, Boston University, Boston, MA, USA.ORCID 0000-0003-4986-4988
Sydney RosenDepartment of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Kathryn DovelPartners in Hope, Lilongwe, Malawi.ORCID 0000-0002-5622-3401
Boston University · USUniversity of California, Los Angeles · USUniversity of the Witwatersrand · ZA

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
Innovative strategies to increase ART Initiation and viral suppression among HIV+ men in MalawiK01TW011484 · FIC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOVEL, KATHRYN L · 2019 to 2023
$717k
FIC NIH HHS K01 TW011484FIC NIH HHS K01-TW011484-01NIAID NIH HHS P30 AI028697NIH HHS AI028697
6 · The paper itself

Abstract

introductionHIV self-testing (HIVST) in outpatient departments (OPD) is a promising strategy for HIV testing in Malawi, given high OPD patient volumes and substantial wait times. To evaluate the relative cost and expected impact of facility-based HIVST (FB-HIVST) at OPDs in Malawi for increasing HIV status awareness, we conducted an economic evaluation of an HIVST cluster-randomized controlled trial.

methodsA cluster-randomized trial was conducted at 15 sites in Malawi from September 2017 to February 2018 with three arms: 1) Standard provider-initiated-testing-and-counselling (PITC); 2) Optimized PITC (additional provider training and job-aids) and 3) FB-HIVST (HIVST demonstration, distribution and kit use in OPD, private kit interpretation and optional HIV counselling). The total production cost per newly identified positive and per person newly initiated on ART were calculated by study arm. These were calculated as the total cost of testing everyone divided by the number of newly identified positives; and the total cost of testing everyone divided by the number of those initiated on ART. Cost-outcomes were calculated under three cost scenarios: (1) full study costs, (2) routine implementation costs and (3) routine implementation + reduced cost for HIVST kits.

resultsThe average cost per person newly diagnosed in the full study cost scenario was $101, $156 and $189, and cost per person initiated on ART was $121, $156 and $279 for Standard PITC, Optimized PITC and FB-HIVST respectively. In the routine implementation cost scenario, the average cost per person newly diagnosed was reduced to $83, and $93, and cost per person initiated on ART to $83, and $137 for Optimized PITC and FB-HIVST respectively. In the negotiated HIVST cost scenario, the average cost per person newly diagnosed was reduced to $55 and cost per person newly initiated on ART reduced to $81 in the FB-HIVST arm.

conclusionsWhile the cost per new ART initiation through FB-HIVST was higher than Standard PITC, FB-HIVST could become cost-saving compared to PITC if the cost of kits is reduced or if treatment linkage rate were increased in the FB-HIVST arm. For high volume OPDs, HIVST may increase facility capacity and increase the number of newly diagnosed positives.

Indexed as

Anti-HIV AgentsCost-Benefit AnalysisCounselingHIV InfectionsHumansMalawiMass ScreeningOutpatientsSelf-TestingAnti-HIV Agentscost-effectivenesseconomic evaluationhealth systemsHIV self-testingmodellingtesting

Identifiers

PMID32909387
PMCPMC7507468
OpenAlexW3086817061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.